<DOC>
	<DOCNO>NCT01091649</DOCNO>
	<brief_summary>The objective study assess relative bioavailability two test tablet formulation ABT-450 compare ABT-450 hard gelatin capsule formulation reference .</brief_summary>
	<brief_title>Study Healthy Adults Evaluate Bioavailability Two Test Tablet Formulations ABT-450</brief_title>
	<detailed_description>This two part study . Part 1 single dose , three period , complete crossover study approximately 21 subject . Part 2 single dose , two period , complete crossover study approximately 20 subject .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion Criteria Overall healthy subject Nonchildbearing potential female include Exclusion Criteria Positive test HAV IgM , HBsAg , antiHCV Ab antiHIV Ab Clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder Use tobacco nicotinecontaining product 6month period prior study drug administration Abnormal screen laboratory result consider clinically significant investigator Pregnant breastfeed female ; requirement OTC and/or prescription medication , vitamins and/or herbal supplement regular basis Previous exposure ABT450</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics , Safety</keyword>
</DOC>